- Home
- SNX vs ROIV Comparison
SNX vs ROIV Comparison
Compare SNX & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNX | ROIV |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4B | 23.2B |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SNX | ROIV |
|---|---|---|
| Price | $242.45 | $34.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $198.70 | $28.94 |
| AVG Volume (30 Days) | 806.4K | ★ 4.6M |
| Earning Date | 03-31-2026 | 05-28-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | ★ 25.16 | N/A |
| EPS | ★ 8.19 | N/A |
| Revenue | ★ $20,053,764,000.00 | $8,260,000.00 |
| Revenue This Year | $9.11 | N/A |
| Revenue Next Year | $5.69 | $744.61 |
| P/E Ratio | $29.66 | ★ N/A |
| Revenue Growth | ★ 17.65 | N/A |
| 52 Week Low | $139.23 | $10.90 |
| 52 Week High | $296.47 | $37.00 |
Technical Indicators
Market Signals| Indicator | SNX | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 42.20 | 57.78 |
| Support Level | $235.16 | $33.56 |
| Resistance Level | $257.93 | $37.00 |
| Average True Range (ATR) | 8.22 | 1.11 |
| MACD | -0.50 | -0.24 |
| Stochastic Oscillator | 36.08 | 41.02 |
Price Performance
Historical ComparisonAbout SNX TD SYNNEX Corporation
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.